Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - Venaxis, Inc.ex99x1.htm
EX-99.2 - EXHIBIT 99.2 - Venaxis, Inc.ex99x2.htm

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
 
        Date of Report (Date of earliest event reported)    November 13, 2012
 
AspenBio Pharma, Inc.
(Exact name of registrant as specified in charter) 

Colorado
001-33675
84-155338
(State or other jurisdiction of incorporation or
organization)
(Commission File Number)
(IRS Employer Identification No.)
     

 
1585 South Perry Street, Castle Rock, CO
80104
(Address of principal executive offices)
(Zip Code)

 
Registrant’s telephone number, including area code (303) 794-2000
 

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


 
 

 

 

Item 8.01.      Other Events.
 
On November 13, 2012, the Company issued a press release titled – “AspenBio Pharma Begins Training Hospital Sites for Pivotal Clinical Trial.”  This press release is filed as Exhibit 99.1 to this Form 8-K.
 
On November 13, 2012, the Company hosted an investor update call.  The script for this investor call is filed as Exhibit 99.2 to this Form 8-K.

Item 9.01.     Financial Statements and Exhibits.
 
(d)           Exhibits
 
Exhibits

99.1
Press release dated November 13, 2012, issued by AspenBio Pharma, Inc. titled “ AspenBio Pharma Begins Training Hospital Sites for Pivotal Clinical Trial.”
 
99.2
Investor update conference call script dated November 13, 2012.
   

 
 
 
 

 
 

 
SIGNATURE
 
 
        Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
   
AspenBio Pharma, Inc.
         (Registrant) 
 
 
Date: November 13, 2012
By:
/s/ Jeffrey G. McGonegal
   
Name:  Jeffrey G. McGonegal
   
Title:    Chief Financial Officer